Clay B Siegall bought $1000K of Immunome (IMNM)
Executed Dec 18 2025, disclosed Dec 18 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Dec 18 2025), the stock returned +18.3% (delay-adjusted); from the execution session (Dec 18 2025), +18.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Clay B Siegall (President and CEO) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Immunome, Inc. (IMNM). Across 5 priced purchase filings, the average 21-session return was +28.7% from execution and +24.2% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of IMNM (46,511 sh × $21.50, as filed), executed Dec 18 2025.
Healthcare · Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-dr…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→25,450 sh × $19.67
Exec Mar 27
Filed Mar 31 · 7:11 AM ET IMNMPURCHASE Immunome, Inc. $100K
4,729 sh × $21.15
Exec Dec 30 2025
Filed Dec 30 2025 · 6:47 PM ET IMNMPURCHASE Immunome, Inc. $149K
7,278 sh × $20.48
Exec Dec 19 2025
Filed Dec 22 2025 · 7:38 AM ET IMNMPURCHASE Immunome, Inc. $999K
137,100 sh × $7.29
Exec Mar 26 2025
Filed Mar 26 2025 · 5:30 PM ET IMNMPURCHASE Immunome, Inc. $1.2M
150,000 sh × $7.75
Exec Jan 31 2025
Filed Feb 3 2025 · 5:30 PM ET IMNMPURCHASE Immunome, Inc. $962K
100,000 sh across 2 lots
Exec Nov 21 2024
Filed Nov 25 2024 · 5:30 PM ET